Literature DB >> 8718439

The development of foot deformities and ulcers after great toe amputation in diabetes.

T L Quebedeaux1, L A Lavery, D C Lavery.   

Abstract

OBJECTIVE: Our aim was to compare the prevalence and severity of foot deformities and the development of ulcerations in patients after a great toe amputations. RESEARCH DESIGN AND METHODS: We evaluated the presence of deformities of the toes and metatarsophalangeal joints (MTPJs) in patients with a great toe amputation who had an intact unamputated contralateral foot. The contralateral foot served as the patient's own control. We used a binomial test for paired data to compare the presence of deformity and ulcer formation and Fisher's exact test to compare joint flexibility in toes and MTPJs with foot deformities.
RESULTS: There were more deformities of the second (P = 0.012) and third (P = 0.002) toes and lesser MTPJs (P < 0.05) and more rigid deformities of the second (P = 0.002) and third (P = 0.016) toes and second MTPJs (P = 0.035) in feet with great toe amputations. New ulcers were more common in feet that had an amputation (P = 0.002).
CONCLUSIONS: We concluded that amputation of the great toe contributes to the development of deformities of the second and third toes and lesser MTPJs and new ulcer formation in patients with diabetes. When deformities were present, the second and third toes and second MTPJ were more severe in feet with a great toe amputation.

Entities:  

Mesh:

Year:  1996        PMID: 8718439     DOI: 10.2337/diacare.19.2.165

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  10 in total

Review 1.  Risk assessment of the diabetic foot and wound.

Authors:  Stephanie Wu; David G Armstrong
Journal:  Int Wound J       Date:  2005-03       Impact factor: 3.315

2.  A novel tendinous interconnection release technique for claw-toe deformity.

Authors:  Tanawat Vaseenon; Phinit Phisitkul
Journal:  Iowa Orthop J       Date:  2010

3.  Efficacy of Early Closed Toe Amputation for Toe Ulcers with Suspected Osteomyelitis after Revascularization for Chronic Limb-Threatening Ischemia.

Authors:  Tsunehiro Shintani; Sachi Suzuki; Naoya Kikuchi; Takumi Ariya; Kayoko Natsume; Kazuhiro Ookura; Jun Okui; Yasunori Sato; Hideaki Obara
Journal:  Ann Vasc Dis       Date:  2022-06-25

4.  Validation of an algorithm to predict reulceration in amputation patients with diabetes.

Authors:  Raúl J Molines-Barroso; José L Lázaro-Martínez; Francisco J Álvaro-Afonso; Irene Sanz-Corbalán; José L García-Klepzig; Javier Aragón-Sánchez
Journal:  Int Wound J       Date:  2016-08-09       Impact factor: 3.315

5.  What are the most effective interventions in preventing diabetic foot ulcers?

Authors:  Lawrence A Lavery; Edgar J G Peters; David G Armstrong
Journal:  Int Wound J       Date:  2008-06       Impact factor: 3.315

6.  Incidence of re-amputation following partial first ray amputation associated with diabetes mellitus and peripheral sensory neuropathy: a systematic review.

Authors:  Sara L Borkosky; Thomas S Roukis
Journal:  Diabet Foot Ankle       Date:  2012-01-20

7.  The Innervated Distally Based First Dorsal Metatarsal Artery Flap with a Wide Pedicle for Reconstruction of a Great Toe Defect.

Authors:  Yohan Lee; Young Ho Lee; Min Bom Kim; Jisu Park; Goo Hyun Baek
Journal:  Clin Orthop Surg       Date:  2019-08-12

Review 8.  Biomechanics of the Diabetic Foot: Consideration in Limb Salvage.

Authors:  Paul J Kim
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-04       Impact factor: 4.730

Review 9.  The system of care for the diabetic foot: objectives, outcomes, and opportunities.

Authors:  Neal R Barshes; Meena Sigireddi; James S Wrobel; Archana Mahankali; Jeffrey M Robbins; Panos Kougias; David G Armstrong
Journal:  Diabet Foot Ankle       Date:  2013-10-10

10.  Possible Advantages of S53P4 Bioactive Glass in the Treatment of Septic Osteoarthritis of the First Metatarsophalangeal Joint in the Diabetic Foot.

Authors:  Matevž Kastrin; Vilma Urbančič Rovan; Igor Frangež
Journal:  J Clin Med       Date:  2021-03-15       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.